<SEC-DOCUMENT>0001213900-26-079276.txt : 20260717
<SEC-HEADER>0001213900-26-079276.hdr.sgml : 20260717
<ACCEPTANCE-DATETIME>20260717172143
ACCESSION NUMBER:		0001213900-26-079276
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260717
DATE AS OF CHANGE:		20260717

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Amesite Inc.
		CENTRAL INDEX KEY:			0001807166
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-PREPACKAGED SOFTWARE [7372]
		ORGANIZATION NAME:           	06 Technology
		EIN:				823431717
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282999
		FILM NUMBER:		261184606

	BUSINESS ADDRESS:	
		STREET 1:		205 EAST WASHINGTON STREET
		STREET 2:		SUITE B
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(650) 516-7633

	MAIL ADDRESS:	
		STREET 1:		205 EAST WASHINGTON STREET
		STREET 2:		SUITE B
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Amesite Operating Co
		DATE OF NAME CHANGE:	20200318
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea0298015-424b5_amesite.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-282999</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<B>To Prospectus Dated December 18, 2024)</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ea029801501_img1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to $2,266,112</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have entered into an At The Market Offering
Agreement (the &ldquo;Sales Agreement&rdquo;) with H.C. Wainwright &amp; Co., LLC (the &ldquo;Sales Agent&rdquo; or &ldquo;Wainwright&rdquo;),
relating to shares of our common stock offered by this prospectus supplement. In accordance with the terms of the Sales Agreement, we
may offer and sell shares of our common stock having an aggregate offering price of up to $2,266,112 from time to time through the Sales
Agent, acting as agent under the prospectus supplement and the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is traded on The Nasdaq Capital
Market under the symbol &ldquo;AMST.&rdquo; On July 16, 2026, the last sale price of our common stock as reported on The Nasdaq Capital
Market was $1.05 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of our common stock, if any, under this
prospectus supplement may be made by any method deemed to be an&nbsp; &ldquo;at the market offering&rdquo; as defined in Rule&nbsp;415
promulgated under the Securities Act of 1933, as amended, including sales made directly on or through The Nasdaq Capital Market, or any
other existing trading market in the United States for our common stock, sales made to or through a market maker other than on an exchange
or otherwise, directly to the Sales Agent as principal, in negotiated transactions at market prices prevailing at the time of sale or
at prices related to such prevailing market prices, and/or in any other method permitted by law. The Sales Agent has agreed to use its
commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between the Sales Agent
and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. If we and Wainwright agree on any
method of distribution other than sales of our ordinary shares on or through the Nasdaq Capital Market or another existing trading market
in the United States at market prices, we will file a further prospectus supplement providing all information about such offering as required
by Rule 424(b) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The compensation to the Sales Agent for sales
of common stock sold pursuant to the Sales Agreement is an aggregate of 3.0% of the gross proceeds of the sales price per share. In connection
with the sale of the common stock on our behalf, the Sales Agent will be deemed to be an &ldquo;underwriter&rdquo; within the meaning
of the Securities Act of 1933, as amended, and the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of July 16, 2026, the aggregate market value
of our outstanding common stock held by non-affiliates was approximately $9,798,344 based on 6,549,851 outstanding shares of common stock,
of which approximately 4,515,366 shares are held by non-affiliates, and a per share price of $2.17 based upon the closing sale price of
our common stock on The Nasdaq Capital Market on May 21, 2026.&nbsp;&nbsp;We have sold $1,000,002.71 of securities pursuant to General
Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date of this prospectus supplement
(excluding this offering). Accordingly, based on the foregoing, we are currently eligible under General Instruction I.B.6 of Form S-3
to offer and sell shares of our common stock having an aggregate offering price of up to approximately $2,266,112. Pursuant to General
Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our
public float in any 12-month period so long as our public float remains below $75.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. You should read the &ldquo;Risk Factors&rdquo; section beginning on&nbsp;page&nbsp;S-5 of this prospectus supplement and
page 5 of the accompanying prospectus and in the documents incorporated by reference in this prospectus supplement for a discussion of
factors to consider before deciding to invest in our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the
accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>H.C. Wainwright &amp; Co.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement is July
17, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE&nbsp;OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS&nbsp;SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-ii</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-4</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-5</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES WE ARE OFFERING</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-9</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; width: 90%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF RIGHTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL OWNERSHIP OF SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT&nbsp;THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
prospectus are part of a registration statement that we filed with the U.S. Securities and Exchange Commission utilizing a &ldquo;shelf&rdquo;
registration process. This document is in two parts. The first part is this prospectus supplement, which describes the specific terms
of this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference
herein. The second part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus,
we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this
prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference herein or
therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided
that if any statement in one of these documents is inconsistent with a statement in another document having a later date&mdash;for example,
a document incorporated by reference in the accompanying prospectus&mdash;the statement in the document having the later date modifies
or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made
solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties
to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties
or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied
on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
in this prospectus supplement or the accompanying prospectus, or incorporated by reference herein or therein. We have not authorized,
and the Sales Agent has not authorized, anyone to provide you with information that is different. The information contained in this prospectus
supplement or the accompanying prospectus, or incorporated by reference herein or therein is accurate only as of the respective dates
thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our securities.
It is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus,
including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider
the information in the documents to which we have referred you in the sections entitled &ldquo;Where You Can Find More Information&rdquo;
and &ldquo;Incorporation of Documents By Reference&rdquo; in this prospectus supplement and in the accompanying prospectus, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering to sell, and seeking offers to
buy, the securities offered by this prospectus supplement only in jurisdictions where offers and sales are permitted. The distribution
of this prospectus supplement and the accompanying prospectus and the offering of the securities offered by this prospectus supplement
in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement
and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities
and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement
and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer
to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which
it is unlawful for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All references in this prospectus supplement and
the accompanying prospectus to &ldquo;Amesite Inc.,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo;
or similar terms refer to Amesite Inc. and its subsidiary taken as a whole, except where the context otherwise requires or as otherwise
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary highlights selected information
contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements included
elsewhere in this prospectus and the information incorporated by reference herein. It does not contain all the information that may be
important to you and your investment decision. You should carefully read this entire prospectus, including the matters set forth under
&ldquo;Risk Factors,&rdquo; and our financial statements and related notes included elsewhere in this prospectus and incorporated by reference
herein. In this prospectus, unless context requires otherwise, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;Amesite,&rdquo;
or &ldquo;the Company&rdquo; refer to Amesite Inc., a Delaware corporation, and its subsidiaries, unless the context otherwise requires.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Amesite is a technology
company focused on building and commercializing AI-powered solutions for the healthcare sector, with particular emphasis on the post-acute
care market. In fiscal 2025, we completed our pivot from an education-centric model to one firmly anchored in the demands and opportunities
of healthcare&mdash;a shift driven by the scale, complexity, and attractive growth potential of this sector.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We operate through two
product lines under our NurseMagic&trade; brand: a B2C (direct-to-practitioner) app and a B2B (enterprise) platform. These solutions directly
address operational, compliance, and efficiency challenges faced by healthcare professionals and organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our B2C NurseMagic&trade;
app connects directly with working nurses and caregivers, providing tools to reduce documentation time, simplify communication, and support
daily workflow. Feedback and usage patterns from these users have been instrumental, allowing us to rapidly refine features and ensure
our offerings are relevant to current industry demands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Building on these real-world
insights, our B2B NurseMagic&trade; solution serves healthcare businesses&mdash;including home health, skilled nursing, hospice, and non-clinical
segments. Enterprises adopting NurseMagic&trade; see improvements in workflow efficiency, data security, and regulatory compliance, all
foundational to driving sustainable business performance. Our offerings are engineered for fast, secure deployment and measurable value
in demanding business environments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We believe that we have
a pathway to deliver AI solutions impactfully, quickly, and compliantly across this expansive, underserved segment. Adoption by both caregivers
and enterprise partners demonstrates the relevance and commercial fit of our technology. Growth in contracted organizations and end users,
alongside positive market feedback, provides further confidence in the direction we have chosen&mdash;even as we remain measured and pragmatic
about future expansion. Significant risks remain for us in the space as we navigate customer, regulatory and user requirements, while
continuing to strive to offer innovative solutions. We face substantial competition from existing players, who have already overcome these
hurdles. Though we are committed to delivering innovation to a space that we believe is hungry for it, we will also have the additional
work of convincing customers to choose our technology-driven approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our Amesite Engage platform,
meanwhile, remains a performant solution for its user base, though we are not dedicating resources to its growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Overall, we believe that
we have consistently endeavored to provide strong fiscal discipline, launching and scaling innovative products while managing costs and
prioritizing efficient resource allocation. We believe this disciplined approach strengthens our potential to grow responsibly, and ultimately,
profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Our Sales and Marketing
Motions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Amesite&rsquo;s go-to-market
strategy for NurseMagic&trade; is distinctly structured for B2C and B2B audiences, leveraging our growing insights from both segments
to build market share, drive recurring revenue, and establish the brand as a trusted, high-value solution for all individual nurses, and
for businesses in post-acute care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>B2C Sales and Marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For individual nurses
and caregivers, we offer a 7-day free trial of NurseMagic&trade;. This approach lowers barriers to adoption and encourages use and adoption
of the app in a timely manner. Our B2C marketing utilizes digital outreach, targeted social media campaigns and community engagement to
increase awareness and credibility. The app&rsquo;s everyday utility and ease-of-use are promoted through user testimonials, while customer
support and product updates sustain positive reviews and word-of-mouth growth. Widespread adoption among practitioners enhances our reputation
and provides invaluable reference points as we approach enterprise buyers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>B2B Sales and Marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our B2B sales effort
targets healthcare enterprises operating in post-acute settings, spanning home health, skilled nursing, hospice, assisted and senior living
centers. Our sales motion is outcome-focused: we identify organizations facing acute staffing and operational pain, then directly connect
with decision-makers. Our B2C solution offers a 7-day free trial, enabling decision-makers to test the app and quickly validate impact
and reduce hesitancy. We emphasize NurseMagic&trade;&rsquo;s potential to save time, support regulatory compliance, enhance documentation
accuracy, and drive measurable improvements in staff efficiency and retention. We strive to deploy rapidly, ensuring business continuity
and value realization. Feedback from both administrators and frontline staff informs product development and strengthens our relationships
with enterprise customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our disciplined, evidence-based
approach in both segments supports Amesite&rsquo;s reputation as a partner that delivers real solutions to pressing business challenges,
helping drive strong adoption, build reference customers, and sustain healthy growth, even in complex, compliance-intensive markets. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Our Technology and
Pipeline</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Amesite&rsquo;s technology
platform is purpose-built to rapidly deliver high-impact, compliant solutions across healthcare and corporate learning. We power both
our NurseMagic&trade; and Amesite Engage products from a coordinated infrastructure built for security, flexibility, and speed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our core architecture
uses modern, best-in-class languages and frameworks for both client and server-side development, supporting robust, scalable front-end
tools. This design gives our engineering team exceptional agility, simplifying the integration of new functionalities and APIs as soon
as they become available. By leveraging both widely adopted technologies and proprietary models, trained on selectively curated datasets,
we aim to deliver meaningful, real-world improvements for our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Notable milestones include
the commercialization of NurseMagic&trade; for both B2C and B2B users, the rollout of an AI-native Electronic Medical Record (EMR), HIPAA-compliant
enterprise workflows, and deployment of features specifically requested by frontline healthcare professionals. We also invested in our
data infrastructure, ensuring continual performance improvement while maintaining data security and compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We collect information
on user behavior and product use, only with full user consent, to drive product enhancements. Our data practices prioritize security,
confidentiality, and compliance with evolving regulations, especially relevant in complex healthcare contexts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Agility is a central
goal of our R&amp;D culture. Our team, benefiting from decades of collective experience in technology, endeavors to deliver continuous
improvement against stringent, best-in-class metrics. We launch more than five new features and capabilities per week, prioritizing those
that solve urgent user problems and are directly usable by our customers. All R&amp;D resources are squarely dedicated to delivering tangible
improvements in user experience and operational impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our deployments are designed
for simplicity and scale: NurseMagic&trade; aims to be fully deployable to every type of employee in an enterprise, requiring no external
system integration, and is administered entirely within the app. Feature sets are intended to be configurable to individual customer needs,
allowing organizations to adapt our solution to their workflows and rapidly realize value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our relentless focus
on innovation, speed, and user impact underpins Amesite&rsquo;s mission to stay ahead of the curve, helping drive customer satisfaction,
adoption, and business performance across rapidly evolving market segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 27, 2026, we entered into a securities
purchase agreement with certain institutional investors, pursuant to which we agreed to sell to such investors, in a registered direct
offering, an aggregate of 696,866 shares of our common stock at a purchase price of $1.435 per share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In a concurrent private placement, we entered
into a securities purchase agreement (the &ldquo;PIPE Purchase Agreement&rdquo; and together with the RD Purchase Agreement, the &ldquo;Purchase
Agreements&rdquo;) with certain institutional investors, pursuant to which we agreed to issue and sell to such investors, (i) pre-funded
warrants to purchase 696,866 shares of common stock, (ii) Series A-1 warrants to purchase an aggregate of 1,393,732 shares of common stock
and (iii) Series A-2 warrants to purchase an aggregate of 1,393,732 shares of common stock at a combined purchase price of $1.434.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, on April 27, 2026, we entered into
a securities purchase agreement with certain of our officers and directors, including Dr. Ann Marie Sastry, Ph.D, our Chairman and CEO,
and George Parmer, a member of our board of directors, pursuant to which we agreed to issue and sell to such officers and directors in
a private placement transaction, (i) an aggregate of 418,118 shares of common stock, (iii) Series A-1 warrants to purchase an aggregate
of 418,118 shares of common stock and (iii) Series A-2 warrants to purchase an aggregate of 418,118 shares of common stock at a combined
purchase price of $1.435.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226, and our telephone number is (734) 876-8141. Our website address is&nbsp;<I>www.amesite.com</I>.
The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information
contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being an Emerging Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company with less than $1.235 billion in
revenues during our last fiscal year, we qualify as an emerging growth company as defined in the Jumpstart Our Business Startups Act (&ldquo;JOBS
Act&rdquo;) enacted in 2012. As an emerging growth company, we expect to take advantage of reduced reporting requirements that are otherwise
applicable to public companies. These provisions include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; disclosure in this prospectus;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&ldquo;Sarbanes-Oxley Act&rdquo;);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may use these provisions until the last day
of our fiscal year following the fifth anniversary of the completion of our initial public offering. However, if certain events occur
prior to the end of such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo; our annual gross revenues exceed
$1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth
company prior to the end of such five-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JOBS Act provides that an emerging growth
company can take advantage of an extended transition period for complying with new or revised accounting standards. As an emerging growth
company, we intend to take advantage of an extended transition period for complying with new or revised accounting standards as permitted
by The JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Offered by Us</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of our common stock having an aggregate offering price of up to $2.266 million.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock to be Outstanding Immediately After this Offering&nbsp;(1)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 8,520,383 shares, after giving effect to the assumed sale of 1,970,532 shares of our common stock at a price of $1.15 per share, which was the closing price of our common stock on the Nasdaq Capital Market on July 9, 2026.&nbsp;&nbsp;The actual number of shares issued will depend on the price at which shares are sold from time to time during this offering.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sales Agent may, according to the terms of the Sales Agreement, sell the shares of our common stock offered under this prospectus supplement in an &ldquo;at-the-market&rdquo; offering.&nbsp;&nbsp;See &ldquo;Plan of Distribution&rdquo; on page S-10 of this prospectus supplement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to use the net proceeds to us from this offering, if any, for general corporate and working capital purposes. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our securities involves a high degree of risk. You should read the &ldquo;Risk Factors&rdquo; section beginning on page S-5 of this prospectus supplement and page 5 of the accompanying prospectus and in the documents incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to invest in our securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Capital Market symbol</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;AMST&rdquo;. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares of common stock to be outstanding immediately after this offering is based on 6,549,851 shares of our common stock outstanding as of &nbsp;July 16, 2026, and excludes, as of such date:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">570,692 shares of common stock issuable upon exercise of outstanding options with a weighted average exercise price of $7.61;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">416,561 shares of common stock issuable upon exercise of outstanding warrants with a weighted average exercise price of $9.20;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,811,850 shares of common stock issuable upon exercise of Series A-1 warrants issued in the April 2026 private placement at an exercise price of $1.435 per share;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,811,850 shares of common stock issuable upon exercise of Series A-2 Warrants issued in the April 2026 private placement at an exercise price of $1.435 per share;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,780 shares of common stock issuable upon exercise of placement agent warrants issued as compensation to the placement agent (or its designees) in connection with the April 2026 registered direct offering at an exercise price of $1.7938 per share; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,781 shares of common stock issuable upon exercise of placement agent warrants issued as compensation to the placement agent (or its designees) in connection with the April 2026 private placement at an exercise price of $1.7938 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated, all information in
this prospectus supplement assumes no exercise of options or warrants described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>RISK&nbsp;FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>An investment in our securities involves a
high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks described below, together
with other information in this prospectus supplement, the accompanying prospectus and the information and documents incorporated by reference
herein and therein. You should also consider the risks, uncertainties and assumptions discussed under the heading &ldquo;Risk Factors&rdquo;
included in our most recent Annual Report on Form 10-K and the subsequent reports that we file with the SEC which are on file with the
SEC and are incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports
we file with the SEC in the future. If any of these risks actually occur, our business, financial condition, results of operations or
cash flow could be adversely effected. This could cause the trading price of our common stock to decline, resulting in a loss of all or
part of your investment. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties
not presently known to us, or that we currently see as immaterial, may also harm our business. Please also read carefully the section
below entitled &ldquo;Special Note Regarding Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to This Offering and Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management team may invest or spend
the proceeds raised in this offering in ways with which you may not agree or which may not yield a significant return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion over
the use of proceeds from this offering&nbsp;and could spend the proceeds in ways that do not improve our results of operations or enhance
the value of our common stock. The failure by management to apply these funds effectively could result in financial losses that could
have a material adverse effect on our business, cause the price of our common stock to decline, and delay the development of our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>You may experience substantial dilution as a result of this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming that an aggregate of 1,970,532 shares
of our common stock are sold at an offering price of $1.15 per share, the last reported sale price of our common stock on the Nasdaq Capital
Market on July 9, 2026, for aggregate gross proceeds of $2.266 million, after deducting estimated offering expenses and sales agent commissions
payable by us, you will experience dilution of approximately $0.81 per share in the net tangible book value of the common stock you purchase
representing the difference between our as adjusted net tangible book value per share after giving effect to this offering and the offering
price per share of common stock. The exercise of outstanding stock options and warrants, including those sold in this offering, will result
in further dilution of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If you purchase securities in this offering,
you may also experience future dilution as a result of future equity offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that significant additional capital
will be needed in the future to continue our planned operations, including research and development, increased marketing, hiring new personnel,
commercializing our products, and continuing activities as an operating public company. To the extent we raise additional capital by issuing
equity securities, our shareholders may experience substantial dilution. We may sell common stock, convertible securities or other equity
securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible
securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales
may also result in material dilution to our existing shareholders, and new investors could gain rights superior to our existing shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We do not intend
to pay cash dividends on our shares of common stock so any returns will be limited to the value of our shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have never paid or
declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable
future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business. Any
future determination to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including
our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and
other factors that our board of directors deems relevant. Therefore, any return to shareholders will be limited to the increase, if any,
of our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We are currently
listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock exchange, our stock
price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more
difficult for our shareholders to sell their securities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Although our common stock
is currently listed on The Nasdaq Capital Market, we may not be able to continue to meet the exchange&rsquo;s minimum listing requirements
or those of any other national exchange. The Listing Rules of Nasdaq require listing issuers to comply with certain standards in order
to remain listed on its exchange. If, for any reason, we should fail to maintain compliance with these listing standards and Nasdaq should
delist our securities from trading on its exchange and we are unable to obtain listing on another national securities exchange, a reduction
in some or all of the following may occur, each of which could have a material adverse effect on our shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the liquidity of our common stock;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market price of our common stock;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain financing for the continuation of our operations;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of investors that will consider investing in our common stock;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of market makers in our common stock;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of information concerning the trading prices and volume of our common stock; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of broker-dealers willing to execute trades in shares of our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sales of a significant number of shares
of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common
stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of a substantial number of shares of our
common stock in the public markets could depress the market price of our common stock and impair our ability to raise capital through
the sale of additional equity securities. We cannot predict the effect that future sales of our common stock would have on the market
price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The shares of common stock offered under
this prospectus supplement and the accompanying base prospectus may be sold in </I></B>&ldquo;<B><I>at the market</I></B>&rdquo; <B><I>offerings,
and investors who buy shares at different times will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors who purchase shares under this prospectus
supplement and the accompanying base prospectus at different times will likely pay different prices, and so may experience different outcomes
in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold,
and there is no minimum or maximum sales price. Investors may experience declines in the value of their shares as a result of sales made
at prices lower than the prices they paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The actual number of shares we will issue
under the sales agreement, at any one time or in total, is uncertain.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain limitations in the sales agreement
and compliance with applicable law, we have the discretion to deliver a sales notice to the Sales Agent at any time throughout the term
of the sales agreement. The number of shares that are sold by the Sales Agent after we deliver a sales notice will fluctuate based on
the market price of the common stock during the sales period and limits we set with the Sales Agent. Because the price per share of each
share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this time to predict
the number of shares, if any, that will ultimately be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_005"></A>SPECIAL&nbsp;NOTE REGARDING
FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the documents incorporated
by reference herein contain forward-looking statements that are based on current management expectations. Statements other than statements
of historical fact included in this prospectus supplement, including statements about us and the future growth and anticipated operating
results and cash expenditures, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (&ldquo;Securities
Act&rdquo;), as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (&ldquo;Exchange Act&rdquo;). When used in
this prospectus supplement the words &ldquo;anticipate,&rdquo; &ldquo;objective,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;can,&rdquo; &ldquo;intend,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo;
&ldquo;potential,&rdquo; &ldquo;plan&rdquo; or the negative of these and similar expressions identify forward-looking statements. These
statements reflect our current views with respect to uncertain future events and are based on imprecise estimates and assumptions and
subject to risk and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
While we believe our plans, intentions and expectations reflected in those forward-looking statements are reasonable, these plans, intentions
or expectations may not be achieved. Our actual results, performance or achievements could differ materially from those contemplated,
expressed or implied by the forward-looking statements contained in, or incorporated by reference into, this prospectus supplement for
a variety of reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge investors to review carefully risks contained
in the section of this prospectus entitled &ldquo;Risk Factors&rdquo; above as well as other risks and factors identified from time to
time in our SEC filings in evaluating the forward-looking statements contained in this prospectus supplement. We caution investors not
to place significant reliance on forward-looking statements contained in this document; such statements need to be evaluated in light
of all the information contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All forward-looking statements attributable to
us or persons acting on our behalf are expressly qualified in their entirety by the risk factors and other cautionary statements set forth,
or incorporated by reference, in this prospectus supplement. Except as required by law, we are under no obligation, and we do not intend,
to update any forward-looking statement, whether as result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>DIVIDEND&nbsp;POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid or declared any cash dividends
on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain
all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends
will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial
condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors that our board of directors
deems relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you invest in our securities in this offering,
your interest will be diluted immediately to the extent of the difference between the effective offering price per share and the as adjusted
net tangible book value per share of common stock after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our pro forma net tangible book value of our common
stock as of March 31, 2026 was approximately $752,422, or $0.11 per share, after giving effect to (i) the issuance of an aggregate of
696,866 shares of common stock in our registered direct offering on April 28, 2026, (ii) the issuance of 418,118 shares of common stock
in our insider-led private placement on April 28, 2026, and (iii) the issuance of 696,866 shares of common stock upon exercise of pre-funded
warrants issued in our registered direct offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After giving effect to the sale of shares of common
stock in the aggregate amount of $2,266,112 in this offering at an assumed offering price of $1.15 per share, as adjusted pro forma net
tangible book value as of March 31, 2026, would have been approximately $3.02 million, or approximately $0.34 per share of common stock.
This represents an immediate increase in net tangible book value of approximately $0.23 per share of common stock to our existing security
holders and an immediate dilution in as adjusted net tangible book value of approximately $0.81 per share of common stock to the purchaser
of shares of common stock in this offering, as illustrated by the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-indent: -9pt; padding-left: 9pt">Assumed offering price per share of common stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Net tangible book value per share as of March 31, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Pro forma net tangible book value per share as of March 31, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase in pro forma net tangible book value per share attributable to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.23</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">As adjusted net tangible book value per share of common stock as of March 31, 2026, after giving effects to this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.34</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dilution in as adjusted pro forma net tangible book value per share of common stock to new investors participating in this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that outstanding exercisable options
or warrants are exercised, you may experience further dilution. In addition, we may need to raise additional capital and to the extent
that we raise additional capital by issuing equity or convertible debt securities your ownership will be further diluted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock to be outstanding
immediately after this offering is based on 4,748,001 shares of our common stock outstanding as of&nbsp;March 31, 2026, and excludes,
as of such date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">290,692 shares of common stock issuable upon exercise of options with a weighted average exercise price of $14.04;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">416,561 shares of common stock issuable upon exercise of warrants with a weighted average exercise price of $9.20;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">696,866 shares of common stock issuable upon exercise of pre-funded warrants issued in our April 2026 private placement at an exercise price of $0.001 per share;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,811,850 shares of common stock issuable upon exercise of Series A-1 warrants issued in our April 2026 private placement at an exercise price of $1.435 per share;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,811,850 shares of common stock issuable upon exercise of Series A-2 warrants issued in our April 2026 private placement at an exercise price of $1.435 per share;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,780 shares of common stock issuable upon exercise of placement agent warrants issued as compensation to the placement agent (or its designees) in connection with our April 2026 registered direct offering and at an exercise price of $1.7938 per share; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48,781 shares of common stock issuable upon exercise of placement agent warrants to be issued as compensation to the placement agent (or its designees) in connection with our April 2026 private placement at an exercise price of $1.7938 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may issue and sell shares of our common stock
having aggregate sales proceeds of up to $2,266,112 from time to time under this prospectus supplement and accompanying base prospectus
and the Sales Agreement. The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and
the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the
Sales Agreement with the Sales Agent as a source of financing. Because there is no minimum offering amount required as a condition to
close this offering, the net proceeds to us, if any, are not determinable at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently intend to use the net proceeds from
the sale of the securities offered hereby, if any, for general corporate and working capital purposes. This expected use of net proceeds
from this offering and our existing cash represents our intentions based upon our current plans and business conditions, which could change
in the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending
on numerous factors. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus supplement,
we cannot predict with certainty all the uses for the net proceeds to be received upon the completion of this offering or the amounts
we will spend on the uses set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering shares of common stock. The following
description of our shares of common stock summarizes the material terms of the shares of common stock and we are offering under this prospectus
supplement and the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a description of the rights associated with
the common stock, see &ldquo;Description of Capital Stock&rdquo; in the accompanying prospectus. Our common stock is listed on The Nasdaq
Capital Market under the symbol &ldquo;AMST.&rdquo; Our transfer agent is Continental Stock Transfer &amp; Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_010"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in">We have entered into the Sales Agreement, dated as
of July 17, 2026, with Wainwright as sales agent, under which we may issue and sell shares of our common stock having an aggregate
offering price of up to the Maximimum Amount (as defined in the Sales Agreement from time to time through Wainwright acting as our sales agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in">The Sales Agreement provides that sales of our common
stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be &ldquo;at-the-market&rdquo;
equity offerings as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales made directly on or through Nasdaq,
the existing trading market for our common stock, or any other existing trading market in the Unites States for our common stock, sales
made to or through a market maker other than on an exchange or otherwise, directly to the sales agent as principal, in negotiated transactions
at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or in any other method permitted
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Wainwright will offer shares of our common stock at prevailing market
prices subject to the terms and conditions of the Sales Agreement as agreed upon by us and Wainwright. We will designate the number of
shares which we desire to sell, the time period during which sales are requested to be made, any limitation on the number of shares that
may be sold in one day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement,
Wainwright will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable laws and
regulations to sell on our behalf all of the shares requested to be sold by us. We or Wainwright may suspend the offering of the shares
of common stock being made through Wainwright under the Sales Agreement at any time upon proper notice to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Settlement for sales of common stock will occur on the first trading
day or any such shorter settlement cycle as may be in effect under Exchange Act Rule 15c6-1 from time to time, following the date on which
any sales are made, or on some other date that is agreed upon by us and Wainwright in connection with a particular transaction, in return
for payment of the net proceeds to us. Sales of our shares of our common stock as contemplated in this prospectus supplement and the accompanying
base prospectus will be settled through the facilities of The Depository Trust Company or by such other means as we and Wainwright may
agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay Wainwright a cash commission of 3.0% of the gross sales
price of the shares of our common stock that Wainwright sells pursuant to the Sales Agreement. Because there is no minimum offering amount
required as a condition to this offering, the actual total offering amount, commissions and proceeds to us, if any, are not determinable
at this time. Pursuant to the terms of the Sales Agreement, we agreed to reimburse Wainwright for the documented fees and costs of its
legal counsel reasonably incurred in connection with entering into the transactions contemplated by the Sales Agreement in an amount not
to exceed $50,000 in the aggregate, in addition to up to a maximum of $3,500 per due diligence update session in connection with a Form
10-Q and $5,000 per due diligence session in connection with a 10-K, for Wainwright&rsquo;s counsel&rsquo;s fees and any incidental expenses
to be reimbursed by us. We will report at least quarterly the number of shares of our common stock sold through Wainwright under the Sales
Agreement, the net proceeds to us and the compensation paid by us to Wainwright in connection with the sales of shares of our common stock.
We estimate that the total expenses for this offering, excluding compensation payable to Wainwright and certain expenses reimbursable
to Wainwright under the terms of the Sales Agreement, will be approximately $72,500.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the sales of shares of our common stock on our behalf,
Wainwright will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, and the compensation paid to Wainwright
will be deemed to be underwriting commissions or discounts. We have agreed in the Sales Agreement to provide indemnification and contribution
to Wainwright against certain liabilities, including liabilities under the Securities Act.&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering of our shares of our common stock pursuant to this prospectus
supplement will terminate upon the earlier of the sale of all of the shares of our common stock provided for in this prospectus supplement
or termination of the Sales Agreement as permitted therein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required by Regulation M, Wainwright will not engage
in any market making activities involving our common stock while the offering is ongoing under this prospectus supplement. Wainwright
and certain of its affiliates have and may in the future provide investment banking and other commercial dealings in the ordinary course
of business with us or our affiliates and have received and may receive customary fees and expenses for these transactions. Wainwright
acted as placement agent for the registered direct offering and private placement in April 2026 and was paid compensation in connection
therewith. In addition, in the ordinary course of its various business activities, Wainwright and its affiliates may make or hold a broad
array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which
may include bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may
involve securities and/or instruments of ours or our affiliates. Wainwright or its affiliates may also make investment recommendations
and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend
to clients that they acquire, long and/or short positions in such securities and instruments.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement and the accompanying base prospectus may
be made available in electronic format on a website maintained by Wainwright, and Wainwright may distribute this prospectus supplement
and the accompanying base prospectus electronically.&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing does not purport to be a
complete statement of the terms and conditions of the Sales Agreement. A copy of the Sales Agreement is included as an exhibit to
our Current Report on Form 8-K expected to be filed with the SEC on July 20, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>LEGAL&nbsp;MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the shares of our common stock
offered hereby will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton&nbsp;LLP, New York, New York.&nbsp; Ellenoff Grossman
&amp; Schole LLP is counsel to the Sales Agent in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statement as of, and for the year
ended June 30, 2025, included in our Annual Report on Form 10-K/A for the year ended June 30, 2025 and incorporated by reference in this
registration statement, have been so incorporated by reference in reliance upon the report of Novogradac &amp; Company LLP, independent
registered public accountants, upon the authority of said firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statement as of, and for the year
ended June 30, 2024, included in our Annual Report on Form 10-K/A for the year ended June 30, 2025 and incorporated by reference in this
registration statement, have been so incorporated by reference in reliance upon the report of Turner, Stone &amp; Company, L.L.P, independent
registered public accountants, upon the authority of said firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_013"></A>WHERE&nbsp;YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the SEC a registration statement
on Form&nbsp;S-3 under the Securities Act, of which this prospectus supplement forms a part.&nbsp;The rules and regulations of the SEC
allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement.
For further information about us and the securities we are offering under this prospectus supplement, you should refer to the registration
statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus
supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement
is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file reports, proxy statements and other information
with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers
that file electronically with the SEC. The address of the SEC&rsquo;s website is <I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We make available free of charge on or through
our website at&nbsp;<I>www.amesite.com</I>, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K
and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable
after we electronically file such material with or otherwise furnish it to the SEC. The information on, or accessible through, our website
is not part of, and is not incorporated into, this prospectus supplement or the accompanying prospectus and should not be considered part
of this prospectus supplement or the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_014"></A>INCORPORATION OF DOCUMENTS
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to incorporate by reference
into this prospectus supplement much of the information we file with the SEC, which means that we can disclose important information to
you by referring you to those publicly available documents. The information that we incorporate by reference is considered to be part
of this prospectus supplement and the accompanying prospectus. Because we are incorporating by reference future filings with the SEC,
this prospectus supplement and the accompanying prospectus are continually updated and those future filings may modify or supersede some
of the information included or incorporated in this prospectus supplement and the accompanying prospectus. This means that you must look
at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus supplement or the
accompanying prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus supplement
and the accompanying prospectus incorporate by reference the documents listed below and any future filings we make with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not
deemed to be filed) until the offering of the securities under the registration statement is terminated or completed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Annual Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390025093213/ea0254427-10k_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended June 30, 2025, filed with the SEC on September 29, 2025;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Amendment to our Annual Report on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390025103104/ea0262762-10ka1_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K/A</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended June 30, 2025, filed with the SEC on October 28, 2025;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Quarterly Reports on Form 10-Q for the quarters ended September 30, 2025, December 31, 2025, and March 31, 2026 filed with the SEC on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390025102257/ea0261871-10q_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 24, 2025</FONT></A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390026012916/ea0274215-10q_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 6, 2026</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390026058512/ea0289734-10q_amesite.htm">May 18, 2026</A>, respectively; </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Current Reports on Form 8-K filed with the SEC on </FONT><A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390025103511/ea026299501-8k_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 29, 2025</FONT></A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390026045782/ea0287089-8k_amesite.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 21, 2026</FONT></A>, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390026048326/ea0287970-8k_amesite.htm">April 28, 2026</A>; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our common stock contained in our Registration Statement on&nbsp;</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1807166/000121390020028010/ea127237-8a12b_amesiteinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 8-A</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;filed with the SEC on September 23, 2020, including any amendments or reports filed with the SEC for the purposes of updating such description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may request, and we will provide you with,
a copy of these filings, at no cost, by calling us at (734) 876-8141 or by writing to us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amesite Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">607 Shelby Street, Suite 700 PMB 214</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Detroit, MI 48226</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn.: Secretary&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029801501_img1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amesite Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">We may offer and sell, from time to time in one
or more offerings, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock
or debt securities, rights, or any combination of the foregoing, either individually or as units comprised of one or more of the other
securities, having an aggregate initial offering price not exceeding $100,000,000.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">This prospectus provides a general description
of the securities we may offer. Each time we sell a particular class or series of securities, we will provide the specific terms of the
securities offered in a supplement to this prospectus. The prospectus supplement and any related free writing prospectus may also add,
update or change information contained in this prospectus. We may also authorize one or more free writing prospectuses to be provided
to you in connection with these offerings. You should read this prospectus carefully, the applicable prospectus supplement and any related
free writing prospectus, as well as any documents incorporated by reference herein or therein before you invest in any of our securities.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">The specific terms of any securities to be offered,
and the specific manner in which they may be offered, will be described in one or more supplements to this prospectus. This prospectus
may not be used to consummate sales of any of these securities unless it is accompanied by a prospectus supplement. Before investing,
you should carefully read this prospectus and any related prospectus supplement.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">Our common stock is presently listed on the Nasdaq
Capital Market under the symbol &ldquo;AMST.&rdquo; On December 10, 2024, the last reported sale price of our common stock was $4.31
per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Capital
Market or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. Prospective purchasers
of our securities are urged to obtain current information as to the market prices of our securities, where applicable.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">These securities may be sold directly by us,
through dealers or agents designated from time to time, to or through underwriters, dealers, or through a combination of these methods
on a continuous or delayed basis. See &ldquo;<I>Plan of Distribution</I>&rdquo; in this prospectus. We may also describe the plan of
distribution for any particular offering of our securities in a prospectus supplement. If any agents, underwriters or dealers are involved
in the sale of any securities in respect of which this prospectus is being delivered, we will disclose their names and the nature of
our arrangements with them in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive
from any such sale will also be included in a prospectus supplement.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">We are a &ldquo;smaller reporting company&rdquo;
under the federal securities laws and, as such, are subject to reduced public company reporting requirements. As of December 10, 2024,
the aggregate market value of our outstanding common stock held by non-affiliates, or public float, was approximately $9.122 million,
based on 2,116,527 shares held by non-affiliates and a price of $4.31 per share, which was the price at which our common stock was last
sold on Nasdaq on December 10, 2024. We have not offered any securities pursuant to General Instruction I.B.6. of Form S-3 during the
prior 12 calendar month period that ends on or includes the date of this prospectus. Pursuant to General Instruction I.B.6. of Form S-3,
in no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more
than one-third of our public float in any 12-month period so long as our public float remains below $75 million. If our public float
decreases, the amount of securities we may sell under our Form S-3 shelf registration statement, including this prospectus, will also
decrease.</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify"><B>Investing in our securities involves various
risks. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 5 for more information on these risks. Additional risks will be described
in the related prospectus supplements under the heading &ldquo;<I>Risk Factors</I>.&rdquo; You should review that section of the related
prospectus supplements for a discussion of matters that investors in our securities should consider.</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify"><B>Neither the U.S. Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities, or passed upon the adequacy or accuracy of this
prospectus or any accompanying prospectus supplement. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is December 18, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="vertical-align: top; width: 90%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_002"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_003"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_004"><FONT STYLE="font-size: 10pt">DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_006"><FONT STYLE="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_007"><FONT STYLE="font-size: 10pt">DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_008"><FONT STYLE="font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_009"><FONT STYLE="font-size: 10pt">DESCRIPTION OF RIGHTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_010"><FONT STYLE="font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_011"><FONT STYLE="font-size: 10pt">LEGAL OWNERSHIP OF SECURITIES</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_012"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_013"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_014"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_015"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="#b_016"><FONT STYLE="font-size: 10pt">INCORPORATION OF DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_001"></A>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This prospectus is part of
a registration statement that we filed with the U.S. Securities and Exchange Commission, or SEC, using a &ldquo;shelf&rdquo; registration
process. Under this shelf registration statement, we may sell from time to time in one or more offerings of common stock and preferred
stock, various series of debt securities and/or warrants to purchase any of such securities, and rights, either individually or as units
comprised of a combination of one or more of the other securities in one or more offerings up to a total dollar amount of $100,000,000.
This prospectus provides you with a general description of the securities we may offer. Each time we sell any type or series of securities
under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This prospectus does not
contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities,
you should refer to the registration statement, including its exhibits. We may add, update or change in a prospectus supplement or free
writing prospectus any of the information contained in this prospectus or in the documents we have incorporated by reference into this
prospectus. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating
to these offerings. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the
documents incorporated by reference into this prospectus and the applicable prospectus supplement, will include all material information
relating to the applicable offering. You should carefully read both this prospectus and the applicable prospectus supplement and any
related free writing prospectus, together with the additional information described under &ldquo;<I>Where You Can Find More Information</I>,&rdquo;
before buying any of the securities being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We have not authorized any
dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference
in this prospectus, any accompanying prospectus supplement or any related free writing prospectus that we may authorize to be provided
to you. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an
accompanying prospectus supplement, or any related free writing prospectus that we may authorize to be provided to you. This prospectus,
the accompanying prospectus supplement and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation
of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, the accompanying
prospectus supplement or any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to
buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You
should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing
prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated
by reference is correct on any date subsequent to the date of the document incorporated by reference (as our business, financial condition,
results of operations and prospects may have changed since that date), even though this prospectus, any applicable prospectus supplement
or any related free writing prospectus is delivered or securities are sold on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We further note that the
representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated
by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the
purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant
to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This prospectus may not be
used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies
between any prospectus supplement, this prospectus and any documents incorporated by reference, the document with the most recent date
will control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">As permitted by the rules
and regulations of the SEC, the registration statement, of which this prospectus forms a part, includes additional information not contained
in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC&rsquo;s web site or
at the SEC&rsquo;s offices described below under the heading &ldquo;<I>Where You Can Find More Information.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Company References</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">In this prospectus &ldquo;the
Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Amesite Inc., a Delaware corporation, and its subsidiaries,
unless the context otherwise requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: center"><B><A NAME="b_002"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify"><I>This summary highlights selected information
that is presented in greater detail elsewhere, or incorporated by reference, in this prospectus. It does not contain all of the information
that may be important to you and your investment decision. Before investing in our securities, you should carefully read this entire
prospectus, including the matters set forth in the section titled &ldquo;Risk Factors&rdquo; and the financial statements and related
notes and other information that we incorporate by reference herein, including our Annual Report on Form 10-K and our Quarterly Reports
on Form 10-Q. Unless the context indicates otherwise, references in this prospectus to &ldquo;Amesite Inc.,&rdquo; &ldquo;we,&rdquo;
&ldquo;our&rdquo; and &ldquo;us&rdquo; refer, collectively, to Amesite Inc., a Delaware corporation.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Amesite Inc. (Nasdaq: AMST)
is a pioneering technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, including its higher
education platform that offers professional learning. Leveraging its proprietary AI infrastructure, Amesite offers cutting-edge applications
that cater to both individual and professional needs. NurseMagic&trade;, the Company&rsquo;s recently launched mobile application,
streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses
on patient care, medications, and handling challenging workplace situations. The Preacto&trade; (beta) is a personal safety application
designed to provide real-time alerts and guidance in the event of emergency situations, including active shooter incidents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><B>The Securities We May Offer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We may offer shares of our
common stock and preferred stock, various series of debt securities and warrants or rights to purchase any of such securities, either
individually or in units, from time to time under this prospectus, together with any applicable prospectus supplement and related free
writing prospectus, at prices and on terms to be determined by market conditions at the time of offering. If we issue any debt securities
at a discount from their original stated principal amount, then, for purposes of calculating the total dollar amount of all securities
issued under this prospectus, we will treat the initial offering price of the debt securities as the total original principal amount
of the debt securities. Each time we offer securities under this prospectus, we will provide offerees with a prospectus supplement that
will describe the specific amounts, prices and other important terms of the securities being offered, including, to the extent applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">designation or classification;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">aggregate principal amount or aggregate offering
    price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">maturity, if applicable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">original issue discount, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">rates and times of payment of interest or dividends,
    if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">redemption, conversion, exchange or sinking fund
    terms, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">conversion or exchange prices or rates, if any,
    and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities
    or other property receivable upon conversion or exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">ranking;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">restrictive covenants, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">voting or other rights, if any; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">important United States federal income tax considerations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">A prospectus supplement and
any related free writing prospectus that we may authorize to be provided to you may also add, update, or change information contained
in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will
offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement
of which this prospectus is a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We may sell the securities
to or through underwriters, dealers or agents or directly to purchasers. We, as well as any agents acting on our behalf, reserve the
sole right to accept and to reject in whole or in part any proposed purchase of securities. Each prospectus supplement will set forth
the names of any underwriters, dealers or agents involved in the sale of securities described in that prospectus supplement and any applicable
fee, commission or discount arrangements with them, details regarding any over-allotment option granted to them, and net proceeds to
us. The following is a summary of the securities we may offer with this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We currently have authorized
100,000,000 shares of common stock, par value $0.0001 per share. As of December 12, 2024, 2,792,440 shares of common stock were issued
and outstanding. We may offer shares of our common stock either alone or underlying other registered securities convertible into or exercisable
for our common stock. Holders of our common stock are entitled to such dividends as our board of directors (the &ldquo;Board of Directors&rdquo;
or &ldquo;Board&rdquo;) may declare from time to time out of legally available funds, subject to the preferential rights of the holders
of any shares of our preferred stock that are outstanding or that we may issue in the future. Currently, we do not pay any dividends
on our common stock. Each holder of our common stock is entitled to one vote per share. In this prospectus, we provide a general description
of, among other things, the rights and restrictions that apply to holders of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We currently have authorized
5,000,000 shares of preferred stock, par value $0.0001 per share. There are currently no shares of preferred stock outstanding. Any authorized
and undesignated shares of preferred stock may be issued from time to time in one or more additional series pursuant to a resolution
or resolutions providing for such issue duly adopted by our Board of Directors (authority to do so being hereby expressly vested in the
Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or
resolutions the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly
unissued series of preferred stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend
rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices,
and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or
any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The rights, preferences,
privileges, and restrictions granted to or imposed upon any series of preferred stock that we offer and sell under this prospectus and
applicable prospectus supplements will be set forth in a certificate of designation relating to the series. We will incorporate by reference
into the registration statement of which this prospectus is a part the form of any certificate of designation that describes the terms
of the series of preferred stock we are offering before the issuance of shares of that series of preferred stock. You should read any
prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of preferred
stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We may offer general debt
obligations, which may be secured or unsecured, senior or subordinated, and convertible into shares of our common stock. In this prospectus,
we refer to the senior debt securities and the subordinated debt securities together as the &ldquo;debt securities.&rdquo; We may issue
debt securities under a note purchase agreement or under an indenture to be entered between us and a trustee and forms of the senior
and subordinated indentures are included as an exhibit to the registration statement of which this prospectus is a part. The indentures
do not limit the amount of securities that may be issued under it and provides that debt securities may be issued in one or more series.
The senior debt securities will have the same rank as all of our other indebtedness that is not subordinated. The subordinated debt securities
will be subordinated to our senior debt on terms set forth in the applicable prospectus supplement. In addition, the subordinated debt
securities will be effectively subordinated to creditors and preferred stockholders of our subsidiaries. Our Board of Directors will
determine the terms of each series of debt securities being offered. This prospectus contains only general terms and provisions of the
debt securities. The applicable prospectus supplement will describe the particular terms of the debt securities offered thereby. You
should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series
of debt securities being offered, as well as the complete note agreements and/or indentures that contain the terms of the debt securities.
Forms of indentures have been filed as exhibits to the registration statement of which this prospectus is a part, and supplemental indentures
and forms of debt securities containing the terms of debt securities being offered will be incorporated by reference into the registration
statement of which this prospectus is a part from reports we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We may offer warrants for
the purchase of shares of our common stock or preferred stock or of debt securities. We may issue the warrants by themselves or together
with common stock, preferred stock or debt securities, and the warrants may be attached to or separate from any offered securities. Any
warrants issued under this prospectus may be evidenced by warrant certificates. Warrants may be issued under a separate warrant agreement
to be entered into between us and the investors or a warrant agent. Our Board of Directors will determine the terms of the warrants.
This prospectus contains only general terms and provisions of the warrants. The applicable prospectus supplement will describe the particular
terms of the warrants being offered thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize
to be provided to you related to the series of warrants being offered, as well as the complete warrant agreements that contain the terms
of the warrants. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference
into the registration statement of which this prospectus is a part from reports we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><B>Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We may issue rights to our
stockholders to purchase shares of our common stock, preferred stock or the other securities described in this prospectus. We may offer
rights separately or together with one or more additional rights, debt securities, preferred stock, common stock or warrants, or any
combination of those securities in the form of units, as described in the applicable prospectus supplement. Each series of rights will
be issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights agent. The rights agent
will act solely as our agent in connection with the certificates relating to the rights of the series of certificates and will not assume
any obligation or relationship of agency or trust for or with any holders of rights certificates or beneficial owners of rights. The
following description sets forth certain general terms and provisions of the rights to which any prospectus supplement may relate. The
particular terms of the rights to which any prospectus supplement may relate and the extent, if any, to which the general provisions
may apply to the rights so offered will be described in the applicable prospectus supplement. To the extent that any particular terms
of the rights, rights agreement or rights certificates described in a prospectus supplement differ from any of the terms described below,
then the terms described below will be deemed to have been superseded by that prospectus supplement. Specific rights agreements will
contain additional important terms and provisions and will be incorporated by reference into the registration statement of which this
prospectus is a part from reports we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We may offer units consisting
of our common stock or preferred stock, debt securities and/or warrants to purchase any of these securities in one or more series. We
may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements
with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit
agent in the applicable prospectus supplement relating to a particular series of units. This prospectus contains only a summary of certain
general features of the units. The applicable prospectus supplement will describe the particular features of the units being offered
thereby. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related
to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements
will contain additional important terms and provisions and will be incorporated by reference into the registration statement of which
this prospectus is a part from reports we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</DIV>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt; width: 98%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company was incorporated
in November 2017. On September 18, 2020, we consummated a reorganizational merger, pursuant to an Agreement and Plan of Merger (the &ldquo;Merger
Agreement&rdquo;), dated July 14, 2020, whereby Amesite Inc. (&ldquo;Amesite Parent&rdquo;), our former parent corporation, merged with
and into us, with our Company resulting as the surviving entity. In connection with the same, we filed a Certificate of Ownership and
Merger with the Secretary of State of the State of Delaware, and changed our name from &ldquo;Amesite Operating Company&rdquo; to &ldquo;Amesite
Inc.&rdquo; The stockholders of Amesite Parent approved the Merger Agreement on August 4, 2020. The directors and officers of Amesite
Parent became our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Pursuant to the Merger Agreement,
on the effective date, each share of Amesite Parent&rsquo;s common stock, $0.0001 par value per share, issued and outstanding immediately
before the effective date, was converted, on a one-for-one basis, into shares of our common stock. Additionally, each option or warrant
to acquire shares of Amesite Parent outstanding immediately before the effective date was converted into and became an equivalent option
to acquire shares of our common stock, upon the same terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Our corporate headquarters
are located at 607 Shelby Street, Suite 700 PMB 214, Detroit, Michigan 48226, and our telephone number is (734) 876-8141. We maintain
a website at www.amesite.com. The contents of, or information accessible through, our website are not part of this prospectus or registration
statement, and our website address is included in this document as an inactive textual reference only. We make our filings with the SEC,
including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports,
available free of charge on our website as soon as reasonably practicable after we file such reports with, or furnish such reports to,
the SEC. The public may read and copy the materials we file with the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, NE,
Washington, D.C. 20549. The public may also obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.
Additionally, the SEC maintains an internet site that contains reports, proxy and information statements and other information. The address
of the SEC&rsquo;s website is www.sec.gov. The information contained in the SEC&rsquo;s website is not intended to be a part of this
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Emerging Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We are an &ldquo;emerging
growth company,&rdquo; as defined in Section 2(a) of the&nbsp;Securities Act, as modified by the Jumpstart Our Business Startups Act
of 2012 (the &ldquo;JOBS Act&rdquo;), and we may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the
auditor attestation requirements of Section 404 of the&nbsp;Sarbanes-Oxley Act&nbsp;of 2002, as amended (the &ldquo;Sarbanes-Oxley Act&rdquo;),
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the
requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments
not previously approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Further, Section 102(b)(1)
of the&nbsp;JOBS Act&nbsp;exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a&nbsp;Securities Act&nbsp;registration statement declared effective or do
not have a class of securities registered under the&nbsp;Exchange Act) are required to comply with the new or revised financial accounting
standards. The&nbsp;JOBS Act&nbsp;provides that a company can elect to opt out of the extended transition period and comply with the
requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We will remain an emerging
growth company for the first five fiscal years after our IPO, unless one of the following occurs: (i) our total annual gross revenues
are $1.235 billion or more, (ii) we have issued more than $1 billion in non-convertible debt in the past three years, or (iii) we become
a &ldquo;large accelerated filer,&rdquo; as defined in&nbsp;Exchange Act Rule 12b-2. References herein to &ldquo;emerging growth company&rdquo;
have the meaning associated with it in the&nbsp;JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Additionally, we are currently
a &ldquo;smaller reporting company&rdquo; as defined in&nbsp;Item 10(f)(1) of&nbsp;Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250
million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our
stock held by non-affiliates is less than $700 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">An investment in our securities
involves a high degree of risk. This prospectus contains, and the prospectus supplement applicable to each offering of our securities
will contain, a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in
our securities, you should carefully consider the specific factors discussed under the heading &ldquo;<I>Risk Factors</I>&rdquo; in this
prospectus and the applicable prospectus supplement, together with all of the other information contained or incorporated by reference
in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks, uncertainties
and assumptions discussed under Item 1A, &ldquo;<I>Risk Factors</I>,&rdquo; in our Annual Report on Form 10-K for the fiscal year ended
June 30, 2024, filed with the SEC on September 30, 2024, and any updates described in our Quarterly Reports on Form 10-Q, all of which
are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with
the SEC in the future and any prospectus supplement related to a particular offering. The risks and uncertainties we have described are
not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also
affect our operations. The occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in
the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_004"></A>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This prospectus and any accompanying
prospectus supplement, including the documents that we incorporate by reference, contains forward-looking statements which are made pursuant
to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section
21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). These statements may be identified by such forward-looking
terminology as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue&rdquo; or the negative
of these terms or other comparable terminology. Our forward-looking statements are based on a series of expectations, assumptions, estimates
and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty.
We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events
could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our
forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent
in our statements regarding:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR>
    <TD STYLE="width: 0.5in; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    planned online machine learning platform&rsquo;s ability to enable universities and other clients to offer timely, improved popular
    courses and certification programs, without becoming software tech companies;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    planned online machine learning platform&rsquo;s ability to result in opportunistic incremental revenue for colleges, universities
    and other clients, and improved ability to garner state funds due to increased retention and graduation rates through use of machine
    learning and natural language processing;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    ability to continue as a going concern;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    ability to obtain additional funds for our operations;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our technologies and our ability to operate our business without
    infringing the intellectual property rights of others;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    reliance on third parties to conduct our business and studies;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    reliance on third party designers, suppliers, and partners to provide and maintain our learning platform;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    ability to attract and retain qualified key management and technical personnel;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act,
    or JOBS Act;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our
    financial performance;</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">the
    impact of government regulation and developments relating to our competitors or our industry; and</FONT></TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">other
    risks and uncertainties, including those listed under the caption &ldquo;Risk Factors.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">All of our forward-looking
statements are as of the date of this prospectus only. In each case, actual results may differ materially from such forward-looking information.
We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material
adverse change in, one or more of the risk factors or risks and uncertainties referred to in this prospectus or included in our other
public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) could materially and adversely affect our business, prospects, financial condition, and results of
operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect
actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements
occurring after the date of this prospectus, even if such results, changes, or circumstances make it clear that any forward-looking information
will not be realized. Any public statements or disclosures by us following this prospectus that modify or impact any of the forward-looking
statements contained in this prospectus will be deemed to modify or supersede such statements in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This prospectus may include
market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys,
publicly available information, reports of governmental agencies and industry publications, articles, and surveys. Industry surveys,
publications, consultant surveys, and forecasts generally state that the information contained therein has been obtained from sources
believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies
and publications are reliable, we have not independently verified market and industry data from third-party sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as described in any
prospectus supplement and any free writing prospectus in connection with a specific offering, we currently intend to use the net proceeds
from the sale of the securities offered under this prospectus for general corporate purposes, capital expenditures, working capital and
general and administrative expenses. We may also use the net proceeds to repay any debts and/or invest in or acquire additional businesses,
products, or technologies on an opportunistic basis, although we have no current commitments with respect to any such investments or
acquisitions as of the date of this prospectus. We have not determined the amount of net proceeds to be used specifically for the foregoing
purposes. As a result, our management will have broad discretion in the allocation of the net proceeds and investors will be relying
on the judgment of our management regarding the application of the proceeds of any sale of the securities. Pending use of the net proceeds,
we intend to invest the proceeds in short-term, investment-grade, interest-bearing instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each time we offer securities
under this prospectus, we will describe the intended use of the net proceeds from that offering in the applicable prospectus supplement.
The actual amount of net proceeds we spend on a particular use will depend on many factors, including, our future capital expenditures,
the amount of cash required by our operations, and our future revenue growth, if any. Therefore, we will retain broad discretion in the
use of the net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_006"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of our capital stock, together with any additional information we include in any applicable prospectus supplement or any related free
writing prospectus, summarizes the material terms and provisions of our common stock and the preferred stock that we may offer under
this prospectus. While the terms we have summarized below will apply generally to any future common stock or preferred stock that we
may offer, we will describe the particular terms of any class or series of these securities in more detail in the applicable prospectus
supplement. For the complete terms of our common stock and preferred stock, please refer to our Certificate of Incorporation and Bylaws
that are incorporated by reference into the registration statement of which this prospectus is a part or may be incorporated by reference
in this prospectus or any applicable prospectus supplement. The terms of these securities may also be affected by Delaware General Corporation
Law (the &ldquo;DGCL&rdquo;). The summary below and that contained in any applicable prospectus supplement or any related free writing
prospectus are qualified in their entirety by reference to our Certificate of Incorporation and our Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is authorized
to issue 105,000,000 shares of capital stock, par value $0.0001 per share, of which 100,000,000 are shares of common stock and 5,000,000
are shares of &ldquo;blank check&rdquo; preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this prospectus,
there were 2,792,440 shares of our common stock issued and outstanding and no shares of preferred stock issued and outstanding</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of our common
stock are entitled to one vote for each share held on all matters to be voted on by the Company&rsquo;s stockholders. There shall be
no cumulative voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividends</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of shares of
our common stock are entitled to dividends when and as declared by the Board from funds legally available therefor if, as and when determined
by the Board of Directors of the Company in their sole discretion, subject to provisions of law, and any provision of the Company&rsquo;s
Certificate of Incorporation, as amended from time to time. There are no preemptive, conversion or redemption privileges, nor sinking
fund provisions with respect to the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Liquidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of any voluntary
or involuntary liquidation, dissolution or winding up of our affairs, the holders of our common stock will be entitled to share ratably
in the net assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other
liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fully Paid and Non-assessable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All outstanding shares of
common stock are duly authorized, validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to issue
up to 5,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, the terms of which may be determined
at the time of issuance by our Board of Directors without further action by stockholders. The terms of any series of preferred stock
may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion
and redemption rights and sinking fund provisions. No preferred stock is currently outstanding. The issuance of any preferred stock could
materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. In particular,
specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets
to, a third party and thereby preserve control by the present management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exclusive Forum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation
provides that unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of
Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought
on behalf of the Company, (b) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent
of the Company to the Company or the Company&rsquo;s stockholders, (c) any action asserting a claim arising pursuant to any provision
of the DGCL, our Certificate of Incorporation or our Bylaws, or (d) any action asserting a claim that is governed by the internal affairs
doctrine, in each such case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants
therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery
or for which the Court of Chancery does not have subject matter jurisdiction. Any person or entity purchasing or otherwise acquiring
any interest in shares of capital stock of the Company are deemed to have notice of and consented to this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, our Certificate
of Incorporation provide that unless the Company consents in writing to the selection of an alternative forum, the federal district courts
of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under
the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company are
deemed to have notice of and consented to this provision. The Supreme Court of Delaware has held that this type of exclusive federal
forum provision is enforceable. There may be uncertainty, however, as to whether courts of other jurisdictions would enforce such a provision,
if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our common stock is Continental Stock Transfer &amp; Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Authorized Number</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors is
expressly authorized to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series,
but not below the number of shares of such series then outstanding. The number of authorized shares of Preferred Stock may be increased
or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the
voting power of the stock of the Company entitled to vote thereon, without a separate vote of the holders of the Preferred Stock, or
of any series thereof, unless a vote of any such holders is required pursuant to the terms of any Certificate of Designation filed with
respect to any series of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Delaware Anti-Takeover Statute</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may become subject to
Section 203 of the Delaware General Corporation Law, which prohibits persons deemed to be &ldquo;interested stockholders&rdquo; from
engaging in a &ldquo;business combination&rdquo; with a publicly held Delaware corporation for three years following the date these persons
become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder
was, approved in a prescribed manner or another prescribed exception applies. Generally, an &ldquo;interested stockholder&rdquo; is a
person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder
status did own, 15% or more of a corporation&rsquo;s voting stock. Generally, a &ldquo;business combination&rdquo; includes a merger,
asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision
may have an anti-takeover effect with respect to transactions not approved in advance by the Board of Directors. A Delaware corporation
may &ldquo;opt out&rdquo; of these provisions with an express provision in its original certificate of incorporation or an express provision
in its certificate of incorporation or bylaws resulting from a stockholders&rsquo; amendment approved by at least a majority of the outstanding
voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us
may be discouraged or prevented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bylaws establish an advance
notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations
of persons for election to our Board of Directors. At an annual meeting, stockholders may only consider proposals or nominations specified
in the notice of meeting or brought before the meeting by or at the direction of our Board of Directors. Stockholders may also consider
a proposal or nomination by a person who was a stockholder at the time of giving notice and at the time of the meeting, who is entitled
to vote at the meeting and who has complied with the notice requirements of the Bylaws in all respects. The Bylaws do not give our Board
of Directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted
at a special or annual meeting of our stockholders. However, the Bylaws may have the effect of precluding the conduct of certain business
at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting
a solicitation of proxies to elect the acquirer&rsquo;s own slate of directors or otherwise attempting to obtain control of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bylaws provide that a
special meeting of our stockholders may be called only by our Secretary at the direction of the Board or by resolution adopted by a majority
of our Board of Directors. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder
consideration of a proposal over the opposition of our Board of Directors by calling a special meeting of stockholders prior to such
time as a majority of our Board of Directors or the Secretary believe the matter should be considered or until the next annual meeting
<I>provided</I> that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting
means that a proposal to replace our Board of Directors also could be delayed until the next annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_007"></A>DESCRIPTION OF DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description,
together with the additional information we include in any applicable prospectus supplements or free writing prospectuses, summarizes
the material terms and provisions of the debt securities that we may offer under this prospectus. We may issue debt securities, in one
or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized
below will apply generally to any future debt securities we may offer under this prospectus, we will describe the particular terms of
any debt securities that we may offer in more detail in the applicable prospectus supplement or free writing prospectus. The terms of
any debt securities we offer under a prospectus supplement may differ from the terms we describe below. However, no prospectus supplement
shall fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in
this prospectus at the time of its effectiveness. As of the date of this prospectus, we have no outstanding registered debt securities.
Unless the context requires otherwise, whenever we refer to the &ldquo;indentures,&rdquo; we also are referring to any supplemental indentures
that specify the terms of a particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will issue any senior
debt securities under the senior indenture that we will enter into with the trustee named in the senior indenture. We will issue any
subordinated debt securities under the subordinated indenture and any supplemental indentures that we will enter into with the trustee
named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration statement, of which this
prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered
will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from
reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures will be qualified
under the Trust Indenture Act of 1939, as amended (the &ldquo;Trust Indenture Act&rdquo;). We use the term &ldquo;trustee&rdquo; to refer
to either the trustee under the senior indenture or the trustee under the subordinated indenture, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summaries of
material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject to, and qualified
in their entirety by reference to, all of the provisions of the indenture and any supplemental indentures applicable to a particular
series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related
to the debt securities that we may offer under this prospectus, as well as the complete indentures that contains the terms of the debt
securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated indenture are identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of each series
of debt securities will be established by or pursuant to a resolution of our Board of Directors and set forth or determined in the manner
provided in an officers&rsquo; certificate or by a supplemental indenture. Debt securities may be issued in separate series without limitation
as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt securities of any series. We will
describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the title;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the principal amount being offered, and if a series,
    the total amount authorized and the total amount outstanding;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">any limit on the amount that may be issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">whether or not we will issue the series of debt
    securities in global form, and, if so, the terms and who the depositary will be;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the maturity date;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">whether and under what circumstances, if any,
    we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether
    we can redeem the debt securities if we have to pay such additional amounts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the annual interest rate, which may be fixed or
    variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and
    the regular record dates for interest payment dates or the method for determining such dates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 49px; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 25px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">whether or not the debt securities will be secured
    or unsecured, and the terms of any secured debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the terms of the subordination of any series of
    subordinated debt;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the place where payments will be made;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on transfer, sale or other assignment,
    if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">our right, if any, to defer payment of interest
    and the maximum length of any such deferral period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the date, if any, after which, and the price at
    which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions
    and the terms of those redemption provisions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">provisions for a sinking fund purchase or other
    analogous fund, if any, including the date, if any, on which, and the price at which we are obligated, pursuant thereto or otherwise,
    to redeem, or at the holder&rsquo;s option, to purchase, the series of debt securities and the currency or currency unit in which
    the debt securities are payable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">whether the indenture will restrict our ability
    or the ability of our subsidiaries, if any, to:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">incur additional indebtedness;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">issue additional securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">create liens;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">pay dividends or make distributions in respect
    of our capital stock or the capital stock of our subsidiaries;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">redeem capital stock;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">place restrictions on our subsidiaries&rsquo;
    ability to pay dividends, make distributions or transfer assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">make investments or other restricted payments;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">sell or otherwise dispose of assets;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">enter into sale-leaseback transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">engage in transactions with stockholders or affiliates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">issue or sell stock of our subsidiaries; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">effect a consolidation or merger;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">whether the indenture will require us to maintain
    any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">a discussion of certain material or special United
    States federal income tax considerations applicable to the debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">information describing any book-entry features;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the applicability of the provisions in the indenture
    on discharge;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">whether the debt securities are to be offered
    at a price such that they will be deemed to be offered at an &ldquo;original issue discount&rdquo; as defined in paragraph (a) of
    Section 1273 of the Internal Revenue Code of 1986, as amended;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the denominations in which we will issue the series
    of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the currency of payment of debt securities if
    other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">any other specific terms, preferences, rights
    or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with
    respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will set forth in the
applicable prospectus supplement the terms under which a series of debt securities may be convertible into or exchangeable for our common
stock, our preferred stock or other securities (including securities of a third party). We will include provisions as to whether conversion
or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares
of our common stock, our preferred stock or other securities (including securities of a third party) that the holders of the series of
debt securities receive would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Consolidation, Merger or Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we provide otherwise
in the prospectus supplement applicable to a particular series of debt securities, the indentures will not contain any covenant that
restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets.
However, any successor to or acquirer of such assets must assume all of our obligations under the indentures or the debt securities,
as appropriate. If the debt securities are convertible into or exchangeable for our other securities or securities of other entities,
the person with whom we consolidate or merge or to whom we sell all of our property must make provisions for the conversion of the debt
securities into securities that the holders of the debt securities would have received if they had converted the debt securities before
the consolidation, merger or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Events of Default under the Indenture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we provide otherwise
in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indentures
with respect to any series of debt securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if we fail to pay interest when due and payable and our failure continues
    for 90 days and the time for payment has not been extended;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if we fail to pay the principal, premium or sinking
    fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has
    not been extended;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if we fail to observe or perform any other covenant
    contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities,
    and our failure continues for 90 days after we receive notice from the trustee or we and the trustee receive notice from the holders
    of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if specified events of bankruptcy, insolvency
    or reorganization occur.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in each
applicable prospectus supplement any additional events of default relating to the relevant series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an event of default with
respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point
above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by
notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal, premium, if any, and
accrued interest, if any, due and payable immediately. If an event of default arises due to the occurrence of certain specified bankruptcy,
insolvency or reorganization events, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities
then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of a majority
in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to
the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless
we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the
indentures, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise
any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities,
unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense.
The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time,
method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on
the trustee, with respect to the debt securities of that series, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the direction so given by the holder is not in
    conflict with any law or the applicable indenture; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">subject to its duties under the Trust Indenture
    Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders
    not involved in the proceeding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures will provide
that if an event of default has occurred and is continuing, the trustee will be required in the exercise of its powers to use the degree
of care that a prudent person would use in the conduct of its own affairs. The trustee, however, may refuse to follow any direction that
conflicts with law or the indenture, or that the trustee determines is unduly prejudicial to the rights of any other holder of the relevant
series of debt securities, or that would involve the trustee in personal liability. Prior to taking any action under the indentures,
the trustee will be entitled to indemnification against all costs, expenses and liabilities that would be incurred by taking or not taking
such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of the debt securities
of any series will have the right to institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other
remedies only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the holder has given written notice to the trustee
    of a continuing event of default with respect to that series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the holders of at least 25% in aggregate principal
    amount of the outstanding debt securities of that series have made a written request and such holders have offered reasonable indemnity
    to the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting
    the proceeding as trustee; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the trustee does not institute the proceeding,
    and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series
    other conflicting directions within 90 days after the notice, request and offer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These limitations do not
apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest
on, the debt securities, or other defaults that may be specified in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will periodically file
statements with the trustee regarding our compliance with specified covenants in the indentures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures will provide
that if a default occurs and is continuing and is actually known to a responsible officer of the trustee, the trustee must mail to each
holder notice of the default within the earlier of 90 days after it occurs and 30 days after it is known by a responsible officer of
the trustee or written notice of it is received by the trustee, unless such default has been cured or waived. Except in the case of a
default in the payment of principal or premium of, or interest on, any debt security or certain other defaults specified in an indenture,
the trustee shall be protected in withholding such notice if and so long as the Board of Directors, the executive committee or a trust
committee of directors, or responsible officers of the trustee, in good faith determine that withholding notice is in the best interests
of holders of the relevant series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Modification of Indenture; Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the
indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without the consent of any
holders with respect to the following specific matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to fix any ambiguity, defect or inconsistency
    in the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to comply with the provisions described above
    under &ldquo;Description of Debt Securities &mdash; Consolidation, Merger or Sale&rdquo;;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to comply with any requirements of the SEC in
    connection with the qualification of any indenture under the Trust Indenture Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to add to, delete from or revise the conditions,
    limitations and restrictions on the authorized amount, terms or purposes of issue, authentication and delivery of debt securities,
    as set forth in the indenture;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to provide for the issuance of, and establish
    the form and terms and conditions of, the debt securities of any series as provided under &ldquo;Description of Debt Securities &mdash;
    General,&rdquo; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any
    series of debt securities, or to add to the rights of the holders of any series of debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to evidence and provide for the acceptance of
    appointment hereunder by a successor trustee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to provide for uncertificated debt securities
    and to make all appropriate changes for such purpose;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to add such new covenants, restrictions, conditions
    or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any
    such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred
    to us in the indenture; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to change anything that does not adversely affect
    the interests of any holder of debt securities of any series in any material respect.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the indentures,
the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of
at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject
to the terms of the indenture for any series of debt securities that we may issue or otherwise provided in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may only make the following changes with the consent of each
holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">extending the stated maturity of the series of
    debt securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">reducing the principal amount, reducing the rate
    of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities;
    or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">reducing the percentage of debt securities, the
    holders of which are required to consent to any amendment, supplement, modification or waiver.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each indenture provides that,
subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series
of debt securities, we may elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">register the transfer or exchange of debt securities
    of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">replace stolen, lost or mutilated debt securities
    of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">maintain paying agencies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">hold monies for payment in trust;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">recover excess money held by the trustee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">compensate and indemnify the trustee; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">appoint any successor trustee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to exercise our
rights to be discharged, we will deposit with the trustee money or government obligations sufficient to pay all the principal of, and
any premium and interest on, the debt securities of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Form, Exchange and Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will issue the debt securities
of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement,
in denominations of $1,000 and any integral multiple thereof. The indentures will provide that we may issue debt securities of a series
in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust
Company or another depositary named by us and identified in a prospectus supplement with respect to that series. See &ldquo;Legal Ownership
of Securities&rdquo; below for a further description of the terms relating to any book-entry securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the option of the holder,
subject to the terms of the indentures and the limitations applicable to global securities described in the applicable prospectus supplement,
the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any
authorized denomination and of like tenor and aggregate principal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms of the
indentures and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt
securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed
thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any
transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer
or exchange, we will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or
other governmental charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will name in the applicable
prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate
for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or
approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in
each place of payment for the debt securities of each series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we elect to redeem the
debt securities of any series, we will not be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">issue, register the transfer of, or exchange any
    debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice
    of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing;
    or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">register the transfer of or exchange any debt
    securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming
    in part.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information Concerning the Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trustee, other than during
the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically
set forth in the applicable indenture and is under no obligation to exercise any of the powers given it by the indentures at the request
of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that
it might incur. However, upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person
would exercise or use in the conduct of his or her own affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless we otherwise indicate
in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to
the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular
record date for the interest payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will pay principal of
and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except
that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail
to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate
the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will
name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular
series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All money we pay to a paying
agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at
the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the
debt security thereafter may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indentures and the debt
securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust
Indenture Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ranking Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The subordinated debt securities
will be unsecured and will be subordinate and junior in priority of payment to certain other indebtedness to the extent described in
a prospectus supplement. The subordinated indenture does not limit the amount of subordinated debt securities that we may issue. It also
does not limit us from issuing any other secured or unsecured debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The senior debt securities
will be unsecured and will rank equally in right of payment to all our other senior unsecured debt. The senior indenture does not limit
the amount of senior debt securities that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_008"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description,
together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes
the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase
common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or together
with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those
securities. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we
will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement
and any applicable free writing prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms
described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer
a security that is not registered and described in this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue the warrants
under a warrant agreement that we will enter into with a warrant agent to be selected by us. If selected, the warrant agent will act
solely as an agent of ours in connection with the warrants and will not act as an agent for the holders or beneficial owners of the warrants.
If applicable, we will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference
from a Current Report on Form 8-K that we file with the SEC, the form of warrant agreement, including a form of warrant certificate,
that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants.
The following summaries of material provisions of the warrants and the warrant agreements are subject to, and qualified in their entirety
by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We
urge you to read the applicable prospectus supplement and any applicable free writing prospectus related to the particular series of
warrants that we sell under this prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms
of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in the applicable
prospectus supplement the terms relating to a series of warrants, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the offering price and aggregate number of warrants
    offered;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the currency for which the warrants may be purchased;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if applicable, the designation and terms of the
    securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount
    of such security;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if applicable, the date on and after which the
    warrants and the related securities will be separately transferable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">in the case of warrants to purchase debt securities,
    the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal
    amount of debt securities may be purchased upon such exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">in the case of warrants to purchase common stock
    or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of
    one warrant and the price at which these shares may be purchased upon such exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the effect of any merger, consolidation, sale
    or other disposition of our business on the warrant agreements and the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the terms of any rights to redeem or call the
    warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">any provisions for changes to or adjustments in
    the exercise price or number of securities issuable upon exercise of the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the dates on which the right to exercise the warrants
    will commence and expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the manner in which the warrant agreements and
    warrants may be modified;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">United States federal income tax consequences
    of holding or exercising the warrants;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the terms of the securities issuable upon exercise
    of the warrants; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">any other specific terms, preferences, rights
    or limitations of or restrictions on the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before exercising their warrants,
holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">in the case of warrants to purchase debt securities,
    the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise
    or to enforce covenants in the applicable indenture; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">in the case of warrants to purchase common stock
    or preferred stock, the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise
    voting rights, if any.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each warrant will entitle
the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe
in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants
may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus
supplement. After the close of business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of the warrants may
exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with specified information,
and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement.
We will set forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the
holder of the warrant will be required to deliver to us or the warrant agent as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon receipt of the required
payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other
office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If
fewer than all of the warrants represented by the warrant certificate are exercised, then we will issue a new warrant certificate for
the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities
as all or part of the exercise price for warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enforceability of Rights by Holders of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If selected, each warrant
agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency
or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants.
A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including
any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may,
without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to
exercise, and receive the securities purchasable upon exercise of, its warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_009"></A>DESCRIPTION OF RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue rights to our
stockholders to purchase shares of our common stock, preferred stock or the other securities described in this prospectus. We may offer
rights separately or together with one or more additional rights, debt securities, preferred stock, common stock or warrants, or any
combination of those securities in the form of units, as described in the applicable prospectus supplement. Each series of rights will
be issued under a separate rights agreement to be entered into between us and a bank or trust company, as rights agent. The rights agent
will act solely as our agent in connection with the certificates relating to the rights of the series of certificates and will not assume
any obligation or relationship of agency or trust for or with any holders of rights certificates or beneficial owners of rights. The
following description sets forth certain general terms and provisions of the rights to which any prospectus supplement may relate. The
particular terms of the rights to which any prospectus supplement may relate and the extent, if any, to which the general provisions
may apply to the rights so offered will be described in the applicable prospectus supplement. To the extent that any particular terms
of the rights, rights agreement or rights certificates described in a prospectus supplement differ from any of the terms described below,
then the terms described below will be deemed to have been superseded by that prospectus supplement. We encourage you to read the applicable
rights agreement and rights certificate for additional information before you decide whether to purchase any of our rights. We will provide
in a prospectus supplement the following terms of the rights being issued:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the date of determining the stockholders entitled to the rights distribution;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the aggregate number of shares of common stock, preferred stock or
    other securities purchasable upon exercise of the rights;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the exercise price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the aggregate number of rights issued;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether the rights are transferrable and the date, if any, on and after
    which the rights may be separately transferred;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the date on which the right to exercise the rights will commence, and
    the date on which the right to exercise the rights will expire;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the method by which holders of rights will be entitled to exercise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the conditions to the completion of the offering, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the withdrawal, termination and cancellation rights, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether there are any backstop or standby purchaser or purchasers and
    the terms of their commitment, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">whether stockholders are entitled to oversubscription rights, if any;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any applicable material U.S. federal income tax considerations; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other terms of the rights, including terms, procedures and limitations
    relating to the distribution, exchange and exercise of the rights, as applicable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each right will entitle the
holder of rights to purchase for cash the principal amount of shares of common stock, preferred stock or other securities at the exercise
price provided in the applicable prospectus supplement. Rights may be exercised at any time up to the close of business on the expiration
date for the rights provided in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders may exercise rights
as described in the applicable prospectus supplement. Upon receipt of payment and the rights certificate properly completed and duly
executed at the corporate trust office of the rights agent or any other office indicated in the prospectus supplement, we will, as soon
as practicable, forward the shares of common stock, preferred stock or other securities, as applicable, purchasable upon exercise of
the rights. If less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly
to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including
pursuant to standby arrangements, as described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Rights Agent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rights agent for any
rights we offer will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_010"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description,
together with the additional information we may include in any applicable prospectus supplements and free writing prospectuses, summarizes
the material terms and provisions of the units that we may offer under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the terms we have summarized
below will apply generally to any units that we may offer under this prospectus, we will describe the particular terms of any series
of units in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ
from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus
or offer a security that is not registered and described in this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will file as exhibits
to the registration statement of which this prospectus is a part, or will incorporate by reference from a Current Report on Form 8-K
that we file with the SEC, the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental
agreements, before the issuance of the related series of units. The following summaries of material terms and provisions of the units
are subject to, and qualified in their entirety by reference to, all the provisions of the unit agreement and any supplemental agreements
applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the particular series
of units that we sell under this prospectus, as well as the complete unit agreement and any supplemental agreements that contain the
terms of the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units comprised
of one or more debt securities, shares of common stock, shares of preferred stock and warrants in any combination. Each unit will be
issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have
the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the
securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will describe in the applicable
prospectus supplement the terms of the series of units, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the designation and terms of the units and of the securities comprising
    the units, including whether and under what circumstances those securities may be held or transferred separately;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any provisions of the governing unit agreement that differ from those
    described below; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any provisions for the issuance, payment, settlement, transfer or exchange
    of the units or of the securities comprising the units.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions described
in this section, as well as those described under &ldquo;<I>Description of Capital Stock</I>,&rdquo; &ldquo;<I>Description of Debt Securities</I>&rdquo;
and &ldquo;<I>Description of Warrants</I>&rdquo; will apply to each unit and to any common stock, preferred stock, debt security or warrant
included in each unit, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Unit Agent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name and address of the
unit agent, if any, for any units we offer will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Issuance in Series</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units in such
amounts and in numerous distinct series as we determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Enforceability of Rights by Holders of Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each unit agent will act
solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency or trust with any
holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no
duty or responsibility in case of any default by us under the applicable unit agreement or unit, including any duty or responsibility
to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit may, without the consent of the
related unit agent or the holder of any other unit, enforce by appropriate legal action its rights as holder under any security included
in the unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, the unit agents and any
of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced by that certificate
for any purpose and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary.
See &ldquo;Legal Ownership of Securities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_011"></A>LEGAL OWNERSHIP OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We can issue securities in
registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those
persons who have securities registered in their own names on the books that we or any applicable trustee or depositary or warrant agent
maintain for this purpose as the &ldquo;holders&rdquo; of those securities. These persons are the legal holders of the securities. We
refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names,
as &ldquo;indirect holders&rdquo; of those securities. As we discuss below, indirect holders are not legal holders, and investors in
securities issued in book-entry form or in street name will be indirect holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Book-Entry Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue securities in
book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or
more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions
that participate in the depositary&rsquo;s book-entry system. These participating institutions, which are referred to as participants,
in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only the person in whose
name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary
or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and
we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants,
which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under
agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, investors in
a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank,
broker or other financial institution that participates in the depositary&rsquo;s book-entry system or holds an interest through a participant.
As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Street Name Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may terminate a global
security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their
own names or in &ldquo;street name.&rdquo; Securities held by an investor in street name would be registered in the name of a bank, broker
or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities
through an account he or she maintains at that institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For securities held in street
name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions
in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all
payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial
owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who
hold securities in street name will be indirect holders, not legal holders, of those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our obligations, as well
as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities.
We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means.
This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the
securities only in global form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, once we make
a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required,
under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly,
we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation
to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the
legal holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up
to the legal holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Considerations for Indirect Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you hold securities through
a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global
securities or in street name, you should check with your own institution to find out:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">how it handles securities payments and notices;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">whether it imposes fees or charges;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">how it would handle a request for the holders&rsquo;
    consent, if ever required;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">whether and how you can instruct it to send you
    securities registered in your own name so you can be a legal holder, if that is permitted in the future;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">how it would exercise rights under the securities
    if there were a default or other event triggering the need for holders to act to protect their interests; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if the securities are in book-entry form, how
    the depositary&rsquo;s rules and procedures will affect these matters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A global security is a security
that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same
global securities will have the same terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each security issued in book-entry
form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its
nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise
in the applicable prospectus supplement, The Depository Trust Company, New York, NY, known as DTC, will be the depositary for all securities
issued in book-entry form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A global security may not
be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special
termination situations arise. We describe those situations below under &ldquo;<I>&mdash; </I>Special Situations When A Global Security
Will Be Terminated.&rdquo; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal
holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global
security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has
an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security
will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the prospectus supplement
for a particular security indicates that the security will be issued as a global security, then the security will be represented by a
global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through
another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Considerations For Global Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an indirect holder, an
investor&rsquo;s rights relating to a global security will be governed by the account rules of the investor&rsquo;s financial institution
and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of
securities and instead deal only with the depositary that holds the global security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If securities are issued
only as global securities, an investor should be aware of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an investor cannot cause the securities to be registered in his or
    her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we
    describe below;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">an investor will be an indirect holder and must
    look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities,
    as we describe above;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">an investor may not be able to sell interests
    in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry
    form;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">an investor may not be able to pledge his or her
    interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or
    other beneficiary of the pledge in order for the pledge to be effective;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the depositary&rsquo;s policies, which may change
    from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&rsquo;s interest in the global
    security. We and any applicable trustee have no responsibility for any aspect of the depositary&rsquo;s actions or for its records
    of ownership interests in the global security. We and the trustee also do not supervise the depositary in any way;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the depositary may, and we understand that DTC
    will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available
    funds, and your broker or bank may require you to do so as well; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">financial institutions that participate in the
    depositary&rsquo;s book-entry system, and through which an investor holds its interest in the global security, may also have their
    own policies affecting payments, notices and other matters relating to the securities. There may be more than one financial intermediary
    in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special Situations When A Global Security
Will Be Terminated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a few special situations
described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those
interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors
must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that
they will be direct holders. We have described the rights of holders and street name investors above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A global security will terminate
when the following special situations occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if the depositary notifies us that it is unwilling,
    unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act
    as depositary within 90 days;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if we notify any applicable trustee that we wish
    to terminate that global security; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if an event of default has occurred with regard
    to securities represented by that global security and has not been cured or waived.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The applicable prospectus
supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities
covered by the prospectus supplement. When a global security terminates, the depositary, and neither we, nor any applicable trustee,
is responsible for deciding the names of the institutions that will be the initial direct holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_012"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
being offered hereby in one or more of the following ways from time to time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">through agents to the public or to investors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">to underwriters for resale to the public or to
    investors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">negotiated transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">block trades;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">directly to investors; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">through a combination of any of these methods
    of sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As set forth in more detail
below, the securities may be distributed from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">at a fixed price or prices, which may be changed;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">at market prices prevailing at the time of sale;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">at prices related to such prevailing market prices;
    or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">at negotiated prices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will set forth in a prospectus
supplement the terms of that particular offering of securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the name or names of any agents or underwriters;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">the purchase price of the securities being offered
    and the proceeds we will receive from the sale;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">any over-allotment options under which underwriters
    may purchase additional securities from us;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">any agency fees or underwriting discounts and
    other items constituting agents&rsquo; or underwriters&rsquo; compensation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">any initial public offering price;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">any discounts or concessions allowed or re-allowed
    or paid to dealers; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">any securities exchanges or markets on which such
    securities may be listed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only underwriters named in
an applicable prospectus supplement are underwriters of the securities offered by that prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If underwriters are used
in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the
terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any
dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented by
managing underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting syndicate is used,
the managing underwriter(s) will be specified on the cover of the prospectus supplement. If underwriters are used in the sale, the offered
securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more transactions,
including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering
price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. Unless otherwise set
forth in the prospectus supplement, the obligations of the underwriters to purchase the offered securities will be subject to conditions
precedent and the underwriters will be obligated to purchase all of the offered securities if any are purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may grant to the underwriters
options to purchase additional securities to cover over-allotments, if any, at the public offering price, with additional underwriting
commissions or discounts, as may be set forth in a related prospectus supplement. The terms of any over-allotment option will be set
forth in the prospectus supplement for those securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we use a dealer in the
sale of the securities being offered pursuant to this prospectus or any prospectus supplement, we will sell the securities to the dealer,
as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of
resale. The names of the dealers and the terms of the transaction will be specified in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell the securities
directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and
we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise,
any agent will act on a best-efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may authorize agents or
underwriters to solicit offers by institutional investors to purchase securities from us at the public offering price set forth in the
prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We
will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale
of the securities, underwriters, dealers or agents may receive compensation from us or from purchasers of the common stock for whom they
act as agents in the form of discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and those
dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters or commissions from the purchasers
for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities, and any institutional
investors or others that purchase common stock directly and then resell the securities, may be deemed to be underwriters, and any discounts
or commissions received by them from us and any profit on the resale of the common stock by them may be deemed to be underwriting discounts
and commissions under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may provide agents and
underwriters with indemnification against particular civil liabilities, including liabilities under the Securities Act, or contribution
with respect to payments that the agents or underwriters may make with respect to such liabilities. Agents and underwriters may engage
in transactions with, or perform services for, us in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may engage in at the market
offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into
derivative transactions with third parties (including the writing of options), or sell securities not covered by this prospectus to third
parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with such a transaction,
the third parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities covered by this prospectus
and the applicable prospectus supplement. If so, the third party may use securities borrowed from us or others to settle such sales and
may use securities received from us to close out any related short positions. We may also loan or pledge securities covered by this prospectus
and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case
of a pledge, sell the pledged securities pursuant to this prospectus and the applicable prospectus supplement. The third party in such
sale transactions will be an underwriter and will be identified in the applicable prospectus supplement or in a post-effective amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To facilitate an offering
of a series of securities, persons participating in the offering may engage in transactions that stabilize, maintain, or otherwise affect
the market price of the securities. This may include over-allotments or short sales of the securities, which involves the sale by persons
participating in the offering of more securities than have been sold to them by us. In those circumstances, such persons would cover
such over-allotments or short positions by purchasing in the open market or by exercising the over-allotment option granted to those
persons. In addition, those persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in
the open market or by imposing penalty bids, whereby selling concessions allowed to underwriters or dealers participating in any such
offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these
transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in
the open market. Such transactions, if commenced, may be discontinued at any time. We make no representation or prediction as to the
direction or magnitude of any effect that the transactions described above, if implemented, may have on the price of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other
than our common stock, which is listed on the Nasdaq Capital Market. We may elect to list any other class or series of securities on
any exchange or market, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class
or series of securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without
notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to comply with the
securities laws of some U.S. states or territories, if applicable, the securities offered pursuant to this prospectus will be sold in
those states only through registered or licensed brokers or dealers. In addition, in some states securities may not be sold unless they
have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement
is available and complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any underwriter may engage
in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Exchange
Act. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids
to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve
purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering
transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be.
If commenced, the underwriters may discontinue any of these activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any underwriters who are
qualified market makers on the Nasdaq Capital Market may engage in passive market making transactions in the securities on the Nasdaq
Capital Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the
commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and
must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the
highest independent bid for such security. If all independent bids are lowered below the passive market maker&rsquo;s bid, however, the
passive market maker&rsquo;s bid must then be lowered when certain purchase limits are exceeded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_013"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the issuance
of the securities offered hereby will be passed upon for us by Sheppard, Mullin, Richter &amp; Hampton LLP, New York, NY. Additional
legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_014"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements
incorporated in this Registration Statement by reference from the Company&rsquo;s Annual Report on Form 10-K have been audited by Turner,
Stone &amp; Company, L.L.P., an independent registered public accounting firm, as stated in their report, which is incorporated herein
by reference. Such financial statements have been so incorporated in reliance upon the report of such firm given upon their authority
as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_015"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus constitutes
a part of a registration statement on Form S-3 filed under the Securities Act. As permitted by the SEC&rsquo;s rules, this prospectus
and any prospectus supplement, which form a part of the registration statement, do not contain all the information that is included in
the registration statement. You will find additional information about us in the registration statement. Any statements made in this
prospectus or any prospectus supplement concerning legal documents are not necessarily complete and you should read the documents that
are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document
or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may read and copy the
registration statement, as well as our reports, proxy statements, and other information, at the SEC&rsquo;s Public Reference Room at
100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information about the operation of the Public
Reference Room. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding
issuers that file electronically with the SEC. The SEC&rsquo;s internet site can be found at http://www.sec.gov. You can also obtain
copies of materials we file with the SEC from our website found at www.amesite.com. Information on our website does not constitute a
part of, nor is it incorporated in any way, into this prospectus and should not be relied upon in connection with making an investment
decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_016"></A>INCORPORATION OF DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed a registration
statement on Form S-3 with the SEC under the Securities Act of 1933, as amended. This prospectus is part of the registration statement,
however the registration statement includes and incorporates by reference additional information and exhibits. The SEC permits us to
&ldquo;incorporate by reference&rdquo; the information contained in documents we file with the SEC, which means that we can disclose
important information to you by referring you to those documents rather than by including them in this prospectus. Information that is
incorporated by reference is considered to be part of this prospectus and you should read it with the same care that you read this prospectus.
Information that we file later with the SEC will automatically update and supersede the information that is either contained, or incorporated
by reference, in this prospectus, and will be considered to be a part of this prospectus from the date those documents are filed. We
have filed with the SEC, and hereby incorporate by reference in this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390024083458/ea0214870-10k_amesite.htm">Form 10-K</A> for the fiscal year ended June 30, 2024 filed with the SEC on September 30, 2024;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our Quarterly Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390024098441/ea0219510-10q_amesite.htm">Form 10-Q</A> for the fiscal quarter ended September 30, 2024 filed with the SEC on November 14, 2024;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390024061535/ea0209462-8k_amesite.htm">July 16, 2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390024102861/ea0222669-8k_amesite.htm">November 26, 2024</A>, and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390024105073/ea0223322-8k_amesite.htm">December 3, 2024</A>;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Our definitive proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390024103454/ea022260701-def14a_amesite.htm">Schedule
    14A</A> for our 2025 Annual Meeting of Stockholders, filed with the Commission on November 27, 2024; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">The description of our common stock and preferred
    stock filed as <A HREF="http://www.sec.gov/Archives/edgar/data/1807166/000121390023081208/f10k2023ex4-3_amesite.htm">Exhibit 4.3</A>
    to our Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1807166/000121390023081208/f10k2023_amesiteinc.htm">Form 10-K</A> for the fiscal year ended June 30, 2023 filed with the SEC on October 6, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also incorporate by reference
all documents (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are
related to such items) that are subsequently filed by us with SEC pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act
prior to the termination of the offering of the securities made by this prospectus (including documents filed after the date of the initial
Registration Statement of which this prospectus is a part and prior to the effectiveness of the Registration Statement). These documents
include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, as well
as proxy statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any statement contained in
this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified
or superseded to the extent that a statement contained in this prospectus or any subsequently filed document that is deemed to be incorporated
by reference into this prospectus modifies or supersedes the statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may request, and we will
provide you with, a copy of these filings, at no cost, by calling us at (734) 876-8141 or by writing to us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Amesite Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">607 Shelby Street, Suite 700 PMB 214</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Detroit, MI 48226</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amesite Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea029801501_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to $2,266,112</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>H.C. Wainwright &amp; Co.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>July 17, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 46; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea029801501_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029801501_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !: 2@# 2(  A$! Q$!_\0
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M#G.,>>G2BV^:I5<N5/3DI0C!2J3KXB;5'#PC&2=5Q4URM'8-?62??O+5/O\
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M!R#R".A'K7)6^KVMW*;>&]M;BX2*&=X(YHW=;>64PQ3%%<L(WE!C63 1I5*
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M?M I%#>2^ ]+U6\TW0?"$-];B[L[GQAKBPM$\YMW6=]&9H[Z6(%EC(:O QW
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M.?$KQ3X&\,SW4+ZG=:5ID(M+_0IX+^59987T'1_$>J:+9.'$BV+LN5CD;/\
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MB96G#X]E_:*_X) ?L,?M"> ;GP_<? OPA\-_$)M]3&A>-OA=I%OX+\3:-K+
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M.>&3YSEB=FX$,2QXSR>*_G2_X+J,C_\ !43]I":)UD@-K\+'69&#1-&WP<\
MHD@D4E"C,I56!P6!4$D$5_5M_P $.OV4OCW^R+^S3XS^'_[0_A2Q\%^,=7^+
MNN^(M.LK'Q'IGB6"XT:]\.^'H[62WNM*DEL8(M]O<6JJ69(Y89(=V8RM?BK_
M ,%4O^"3G[='[0_[>'QL^-_P@^$>F>(_AYXNL_ LOAO7K_QSX3T?4+RX\/\
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MYMP1@GD^.SC,<RC-Y;FV+PF)BZL*4\.YR2G*]6M*UX4[2IW=TZ7[''_!5O\
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M--(BLL4,,OBC3$\V0J@>%8]P88./_P $&?V%?VG/V,['X^+^T-\/8/!C^/\
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M[-Q;V7B#5=:U?Q3J&G6K.PMWMK:2RL]-6>.+9F( 0*X*I&J8 ^+M#_X*Z_\
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
